Navigation Links
New technology to speed up research into Huntington's disease

A new tool developed at Cambridge University represents a breakthrough in the race to find treatments to help sufferers with Huntington's disease.

Researchers have developed an effective new method of testing cognitive decline in mice with the disease, using an automated touch screen. It is hoped the screen will also allow researchers to study more effectively the cognitive difficulties in other neurodegenerative disorders such as in Alzheimer's and CJD.

Huntington's disease is a genetic disease affecting around 8 in 100,000 people. It is characterised by a progressive decline in cognitive functioning (including memory loss, intellectual decline and disorientation) together with the appearance of abnormal movements and impaired motor skills (such as unsteady gait and poor coordination).

There is currently no cure and whilst some symptoms can be alleviated, no treatments have been developed that help with cognitive deficits, a distressing aspect of the disease.

Whilst useful mouse models mimicking this disorder have been developed, it has been difficult to test cognitive skills such as learning, because most traditional experiments demand a level of physical performance that the mice cannot deliver due to the effect of the disease on their motor abilities.

The automated screen developed by Cambridge scientists provides a simple means of assessing cognition, in a way that requires minimal movement on the part of the mouse. The mouse makes its response by touching its nose to the touch-sensitive screen. This means that the HD mice can complete the task, despite motor problems.

Other benefits are that it is less labour intensive, less time consuming and less stressful for mice, compared to traditional testing methods. Given the difficulties associated with these traditional methods, progress to date in trialling new treatments for cognitive deficits has been slow with contract research organisations understan dably reluctant to engage with such research. Given the ease of use of the touch screen system, it is hoped this will change.

Dr Jenny Morton, Dr Lisa Saksida and Dr Tim Bussey from the Departments of Pharmacology and Experimental Psychology at the University of Cambridge, who led the research, tested normal mice and mice carrying the HD gene mutation. The task set was a choice between two visual stimuli on a touch-sensitive computer screen. If a mouse touched the correct stimulus, it was rewarded with food pellets; if it touched the incorrect stimulus, the lights went out and the mouse did not get a reward. Both normal and HD mice learnt to touch the correct stimulus with their noses and were able to learn the correct stimulus to obtain a reward by day 10.

The researchers also demonstrated that when the stimuli were reversed (so the stimulus that had previously been correct was now incorrect), HD mice struggled with the task although younger HD mice, who had not progressed as far in the disease, eventually learned it. When the mice were then presented with a new pair of stimuli, this proved too difficult even for the younger HD mice.

Importantly, and where the screen is so valuable, all the HD mice were physically able to complete the task (i.e. they were able physically to touch the screen and obtain rewards, even though their responses were often incorrect). This indicates that their poor cognitive performance was not secondary to motor impairments. It also confirms that mice with HD have cognitive problems that worsen with increasing age.

Dr Morton said, "We are very excited about the results from the touchscreen apparatus. For many HD patients, the cognitive and emotional symptoms are as disabling as the more obvious motor effects of the disease, and much effort is focused on understanding cognitive decline in HD".

"Useful cognitive testing has been a bottle-neck in developing new treatments for this aspect of HD. The touchscreen system should make it easier to test drugs for treating cognitive decline in HD."

It is hoped the touchscreen system will also be valuable for testing cognition in animals with other types of neurological dysfunction such as Alzheimer's disease or prion disease, and particularly where motor deficits make cognitive testing difficult or impractical. Dr Morton said "we are pleased at just how effective the test was and already clinical trial companies are showing an interest in the touch screen system".
'"/>

Source:University of Cambridge


Related biology news :

1. Novel technology detects human DNA mutations
2. Novel antiviral technology inhibits RSV infection in mice
3. The BIOS Initiative - open source biotechnology is born
4. Revolutionary nanotechnology illuminates brain cells at work
5. Study: homemade gene expression technology unreliable
6. First technology to remove prions that cause vCJD from blood launched
7. Integration of Agilents MS technology, Proteome Systems software to help scientists in proteomics research
8. Agilent Technologies new genome analysis technology set to accelerate Australia fight against mesothelioma
9. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
10. First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology
11. Vietnam war technology could aid elephant conservation

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... to announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. ... years, is proud to add Target to its list of well-respected retailers. This ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
Breaking Biology Technology: